Holen Sie sich die Stockscreener-App
66.26
1.18%
0.66
Schlusskurs vom Vortag:
$65.60
Offen:
$64.01
24-Stunden-Volumen:
1.20M
Relative Volume:
0.39
Marktkapitalisierung:
$8.63B
Einnahmen:
$638.78M
Nettoeinkommen (Verlust:
$-22.66M
KGV:
-379.93
EPS:
-0.1744
Netto-Cashflow:
$122.18M
1W Leistung:
+7.66%
1M Leistung:
+27.57%
6M Leistung:
+217.43%
1J Leistung:
+391.67%
1-Tages-Spanne:
$63.50
$67.18
1-Wochen-Bereich:
$60.35
$67.18
52-Wochen-Spanne:
$11.16
$67.18
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
66.21 | 8.55B | 638.78M | -22.66M | 122.18M | -0.1744 |
VEEV
Veeva Systems Inc
|
262.50 | 42.88B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
61.95 | 12.38B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
62.22 | 11.67B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
92.97 | 7.72B | 1.34B | 230.70M | 440.96M | 2.6695 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Eingeleitet | Piper Sandler | Neutral |
| 2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
Macrogen to offer 10x Genomics spatial biology platform in Asia first - Korea Biomedical Review
10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100 - GuruFocus
10x Genomics (TXG) director offloads 20,000 shares in open-market trades - Stock Titan
T. Rowe Price reports 10%+ holding in 10x Genomics (TXG) - Stock Titan
Stifel reiterates Buy rating on 10X Genomics stock - Investing.com
10x Genomics (TXG) CEO holds 1,075,249 shares after 100-share gift - Stock Titan
Founder trust at 10x Genomics (NASDAQ: TXG) moves to sell 20,000 shares - Stock Titan
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? - Yahoo Finance
TXG Stock Price and Chart — NASDAQ:TXG - TradingView
A Look at 10x Genomics Inc (TXG) After 4.0% Decline -- GF Value $18.36 vs Price $60.00 - GuruFocus
RBC Capital initiates 10X Genomics stock with Sector Perform rating - Investing.com
10X GENOMICS, INC. : RBC INITIATES COVERAGE WITH SECTOR PERFORM RATING; TARGET PRICE $70 - Bitget
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit - Benzinga
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences - TradingView
Delaware jury finds Parse infringed three genetic-sequencing patents - Reuters
10x Genomics Inc (TXG) Shares Fall 5.1% -- GF Value Says Still O - GuruFocus
10x Genomics (TXG) CEO sells 10,486 shares under 10b5-1 plan - Stock Titan
10x Genomics wins jury award in Qiagen patent row (TXG:NASDAQ) - Seeking Alpha
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences - Porterville Recorder
10x Genomics CEO Serge Saxonov sells $667,900 in stock - Investing.com
10x Genomics Inc (TXG) Director Shehnaaz Suliman Sells 2,207 Sha - GuruFocus
10x Genomics (NASDAQ: TXG) CEO sells for taxes, still holds 1,085,835 shares - Stock Titan
10x Genomics (NASDAQ: TXG) CEO lines up another share sale - Stock Titan
10x Genomics (NASDAQ: TXG) exec to sell 16,614 shares - Stock Titan
10x Genomics (NASDAQ: TXG) insider plans sale of 17,948 shares - Stock Titan
10x Genomics (NASDAQ: TXG) holder to sell about $871K in stock - Stock Titan
10x Genomics (TXG) CEO gifts 4,000 shares in stock donation - Stock Titan
10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade) (TXG) - Seeking Alpha
Fed. Circ. Backs PTAB's Ax Of 10x Genomics Patent Claims - law360.com
Federal Circuit Upholds PTAB Obviousness Rulings Against Single Cell Sequencing Patents - IPWatchdog.com
10x Genomics Gains as Investors Extend Post-Earnings Rally on Atera Demand - Quiver Quantitative
10x Genomics’ Bid to Revive Patents Rejected by Federal Circuit - Bloomberg Law News
10x Genomics (NASDAQ:TXG) Reaches New 52-Week HighWhat's Next? - MarketBeat
10x Genomics stock hits 52-week high at $60.73 By Investing.com - Investing.com Australia
10x Genomics stock hits 52-week high at $60.73 - Investing.com
Bank of America Corp DE Has $20.48 Million Position in 10x Genomics $TXG - MarketBeat
Director Sarah Teichmann Sells 7,551 Shares of 10x Genomics Inc (TXG) - GuruFocus
10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform - Yahoo Finance
A Look at 10x Genomics Inc (TXG) After 3.4% Gain -- GF Value $18 - GuruFocus
10x Genomics Inc (TXG) (Q2 2026) Earnings Call Highlights: Atera Launch Drives Record Demand Amidst Transition - GuruFocus
10x Genomics (NASDAQ: TXG) director sells under 10b5-1 plan - Stock Titan
7 Best Genomics Stocks for 2026 and How to Invest - The Motley Fool
symbol__ Stock Quote Price and Forecast - CNN
10x Genomics (TXG) Could Be 35% Above Fair Value Following 2026 Outlook Lift - Yahoo Finance
10x Genomics (TXG) Dips 3.5% to $56.09 as Support at $53.29 Comes Into ViewTrend Reversal Picks - Vinanet
5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call - Yahoo Finance
Cathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital By Investing.com - Investing.com Canada
Cathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital - Investing.com
A Look at 10x Genomics Inc (TXG) After 3.6% Decline -- GF Value $18.38 vs Price $56.09 - GuruFocus
TXG (TXG) insider schedules sale of common stock and notes prior sale - Stock Titan
ARK Investment Management (TXG) reports 10.0M-share position in 10x Genomics - Stock Titan
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.02%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):